Associated tags: Therapy, Autoimmunity, Pain management, Allosteric regulation, Good, DSM-IV codes, TGF, Partner, Science, Toxicity, Pharmaceutical industry, Patient, Roche, IL-12, Cancer, PD-1, Software, Engineering, Cytokine, Health Technology, Health
Locations: WASHINGTON, UNITED STATES, NORTH AMERICA, CA
Biotechnology,
Health Technology,
Pharmaceutical,
Health,
Safety,
Cancer,
Doctor of Philosophy,
Conference,
Roche,
Therapy,
Acquisition,
Art The in vivo safety and efficacy data described in this poster demonstrate that this program is suitable for clinical development.
Key Points:
- The in vivo safety and efficacy data described in this poster demonstrate that this program is suitable for clinical development.
- Bonum is developing new therapies based on its proprietary platform of conditionally active therapeutics.
- The company is a spinout of Good Therapeutics, which developed the technology that Bonum is advancing.
- The merits of the platform were validated by the Roche acquisition of Good Therapeutics for its PD-1-regulated IL-2 program in September 2022.
Biotechnology,
Health Technology,
Pharmaceutical,
Health,
Therapy,
Acquisition,
Engineering,
IL-12,
Doctor of Philosophy,
Roche,
Safety,
AACR,
Cell,
IL2,
Cytokine,
Patient,
Poster,
Biology,
TGF,
Pharmaceutical industry Scientists from Bonum will present these data in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, CA.
Key Points:
- Scientists from Bonum will present these data in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, CA.
- The in vivo safety and efficacy data described in the poster demonstrate that this program is suitable for progressing into the clinic.
- John Mulligan, PhD, Bonum Therapeutics’ CEO, commented, “We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.”
The poster will be available on the Bonum website on the day of the presentation.
- The merits of the platform were validated by the Roche acquisition of Good Therapeutics and its PD-1-regulated IL-2 program in September 2022.
Retrieved on:
Tuesday, November 15, 2022
Science,
Software,
Biotechnology,
Research,
Pharmaceutical,
Health,
Health Technology,
Technology,
Cytokine,
Partner,
TGF,
Partnership,
Pain management,
Engineering,
Therapy,
Toxicity,
PD-1,
Cancer,
Acquisition,
Allosteric regulation,
IL-12,
Autoimmunity,
Roche,
Patient,
Pharmaceutical industry,
Good,
Bonum Bonum Therapeutics , a biopharmaceutical company using allosteric regulation to create conditionally active and less toxic medicines, today announced a $93 million Series A financing.
Key Points:
- Bonum Therapeutics , a biopharmaceutical company using allosteric regulation to create conditionally active and less toxic medicines, today announced a $93 million Series A financing.
- Bonum is developing new therapies based on the proprietary platform of allosterically regulated, conditionally active therapeutics developed by Good Therapeutics.
- The value of the platform was validated by the Roche acquisition of Good Therapeutics and its PD-1 regulated IL-2 program.
- Bonum Therapeutics is focused on the generation of a new class of therapeutics based on a proven technology platform.
